MILAN—Italy's antitrust authority fined Novartis AG and Roche Holding AG more than €90 million ($123.6 million) each Wednesday after finding the Swiss pharmaceutical giants had colluded to channel demand to an expensive drug used to combat serious vision problems.. The Italian Competition Authority said the two companies agreed to push doctors toward their jointly marketed Lucentis treatment, an expensive drug used to combat sight problems such as age-related macular degeneration, at the expense of Roche's Avastin, an older...
  